These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7250178)

  • 1. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites.
    Juma FD; Rogers HJ; Trounce JR
    Eur J Clin Pharmacol; 1981; 19(6):443-51. PubMed ID: 7250178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites].
    Wagner T; Heydrich D; Bartels H; Hohorst HJ
    Arzneimittelforschung; 1980; 30(9):1588-92. PubMed ID: 7193030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of liver failure on the pharmacokinetics of cyclophosphamide.
    Juma FD
    Eur J Clin Pharmacol; 1984; 26(5):591-3. PubMed ID: 6468474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of temocillin (BRL 17421) in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Fillastre JP; Borsa F; Godin M
    J Antimicrob Chemother; 1983 Jul; 12(1):47-58. PubMed ID: 6619046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of pioglitazone in patients with impaired renal function.
    Budde K; Neumayer HH; Fritsche L; Sulowicz W; Stompôr T; Eckland D
    Br J Clin Pharmacol; 2003 Apr; 55(4):368-74. PubMed ID: 12680885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients.
    Rouan MC; Binswanger U; Bammatter F; Theobald W; Schoeller JP; Guibert J
    J Antimicrob Chemother; 1984 Jun; 13(6):611-8. PubMed ID: 6088464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of temocillin in patients with normal and impaired renal function.
    Boelaert J; Daneels R; Schurgers M; Lambert AM; Van Landuyt HW; Mellows G; Wolf J; Swaisland AJ
    J Antimicrob Chemother; 1983 Apr; 11(4):349-56. PubMed ID: 6853404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of metronidazole in patients with varying degrees of renal failure.
    Houghton GW; Dennis MJ; Gabriel R
    Br J Clin Pharmacol; 1985 Feb; 19(2):203-9. PubMed ID: 3986078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function.
    Braun J; Kollert JR; Becker JU
    Eur J Clin Pharmacol; 1987; 31(6):711-4. PubMed ID: 3104059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The disposition of cyclophosphamide in a group of myeloma patients.
    Bramwell V; Calvert RT; Edwards G; Scarffe H; Crowther D
    Cancer Chemother Pharmacol; 1979; 3(4):253-9. PubMed ID: 535136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefodizime in patients with various degrees of renal failure.
    Loffreda A; Lampa E; Lucarelli C; Amorena M; Contaldi C; Calderaro V; Rossi F
    Chemotherapy; 1999; 45(1):1-7. PubMed ID: 9876203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between renal function and disposition of oral cefixime.
    Dhib M; Moulin B; Leroy A; Hameau B; Godin M; Johannides R; Fillastre JP
    Eur J Clin Pharmacol; 1991; 41(6):579-83. PubMed ID: 1815970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship.
    Kleinbloesem CH; van Brummelen P; van Harten J; Danhof M; Breimer DD
    Clin Pharmacol Ther; 1985 May; 37(5):563-74. PubMed ID: 3987180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of cyclophosphamide.
    Moore MJ
    Clin Pharmacokinet; 1991 Mar; 20(3):194-208. PubMed ID: 2025981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nizatidine disposition in subjects with normal and impaired renal function.
    Aronoff GR; Bergstrom RF; Bopp RJ; Sloan RS; Callaghan JT
    Clin Pharmacol Ther; 1988 Jun; 43(6):688-95. PubMed ID: 2897890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Half-life of oxazaphosphorines in biological fluids.
    Sladek NE; Powers JF; Grage GM
    Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
    Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacological studies with the vasodilator endralazine in patients with renal impairment.
    Elliott HL; Meredith PA; Sloan L; Reid JL
    Eur J Clin Pharmacol; 1984; 27(2):159-63. PubMed ID: 6499896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
    Sladek NE; Doeden D; Powers JF; Krivit W
    Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.